Rosacea

Rosacea is a chronic, relapsing inflammatory disorder of the central face. It typically begins with recurrent, transient flushing and persistent centrofacial erythema, and can progress — though not inevitably — to visible telangiectasia (dilated blood vessels), inflammatory papules and pustules, and, in a minority of patients, irreversible thickening and glandular overgrowth of the skin (phymatous change), most often affecting the nose.^[1] Its pathophysiology is not fully elucidated but is thought to involve a combination of genetic predisposition, neurovascular dysregulation, and an overactive innate immune response, with ultraviolet exposure and Demodex folliculorum mite density proposed as contributors to this inflammatory cascade.^[1] More than half of patients with cutaneous rosacea also have some degree of ocular involvement — irritation, dryness, blepharitis — which can precede the skin findings entirely and is frequently under-recognized unless specifically asked about. Current management is organized around the specific features (phenotype) a patient has, rather than around older subtype labels, since treatment genuinely differs by phenotype and a single patient commonly has more than one at once.^[2]

Papulopustular rosacea — centrofacial erythema and telangiectasia with inflammatory papules, no comedones. (M. Sand et al., CC BY 2.0, Wikimedia Commons)

Rhinophyma — the most common site of phymatous change, more frequent in men and developing over years. (M. Sand et al., CC BY 2.0, Wikimedia Commons)

Ocular rosacea — lid margin telangiectasia and conjunctival injection; can precede visible skin findings. (Weinstock LB, Myers TL, CC BY 4.0, Wikimedia Commons)

Diagnostic approach (2017 National Rosacea Society classification)

Rosacea is diagnosed clinically using a phenotype-based approach rather than a fixed checklist.^[1][3]

• Family history of rosacea.
• Lightly pigmented skin — though rosacea occurs in all skin tones and is likely underdiagnosed in darkly pigmented skin because the visual findings differ (see Recognize the Condition).
• Onset typically in the late 20s to 40s — later than the usual onset of acne vulgaris, a useful clue when the two are hard to distinguish.
• Similar prevalence between sexes overall, though phymatous change is more common in men.
• A personal history of frequent flushing or sun sensitivity.
• Comorbid conditions with growing evidence of association — migraine, inflammatory bowel disease, depression, and cardiovascular disease — suggesting rosacea may be a marker for, not just a consequence of, a broader inflammatory process.

Differentiating rosacea from its common mimics

Rosacea is diagnosed clinically, and its most important mimics are managed completely differently — some (a steroid-induced rosacea-like eruption) actually get worse with the instinctive reflex reach for a topical corticosteroid, and others (discoid lupus erythematosus) need a systemic workup, not a skin cream.

Papulopustular rosacea — centrofacial erythema and telangiectasia with inflammatory papules, no comedones. (M. Sand et al., CC BY 2.0, Wikimedia Commons)

Acne vulgaris, for comparison — comedones (open and closed) are present, which rosacea never has. (Dr. Gandikota Raghurama Rao, CC BY 4.0, Wikimedia Commons)

Steroid-induced rosacea-like eruption — worsens with continued topical corticosteroid use and improves only after stopping it, not with more topical treatment. (Corinna Kennedy, CC BY-SA 4.0, Wikimedia Commons)

History

• Onset age and pattern — rosacea typically starts in the late 20s to 40s, later than the usual onset of acne vulgaris.
• Ask specifically about flushing triggers (sun, heat, wind, exercise, hot beverages, spicy food/vinegar, alcohol, emotional stress, astringent skincare products) and about medications that can worsen rosacea (see Non-Pharmacologic Treatment).
• Ask specifically about eye symptoms — irritation, grittiness, dryness, recurrent styes, or blepharitis — since ocular involvement can precede skin findings and is easy to miss if not asked about directly.
• Ask about any topical corticosteroid use on the face, prescribed or over-the-counter, which can both cause a rosacea-like eruption and worsen true rosacea.
• Family history of rosacea.

Examination

• Inspect the pattern and distribution of erythema, remembering that redness may appear dusky, brown, grey, or purple rather than red in darkly pigmented skin.
• Look specifically for the absence of comedones — their presence points away from rosacea and toward acne vulgaris (combined rosacea plus acne does occur).
• Examine the nose, chin, forehead, ears, and cheeks for early phymatous change (thickened, bumpy texture) even before frank rhinophyma is obvious.
• Examine the eyelid margins and conjunctiva for telangiectasia, injection, or blepharitis in every patient with cutaneous rosacea, not only those who report eye symptoms.

Investigations

Rosacea is a clinical diagnosis — no laboratory test or biopsy is routinely needed.^[4] Consider a skin biopsy or referral for further workup specifically when the presentation is atypical or a mimic is suspected: an asymmetric or ulcerated phymatous lesion (exclude skin cancer), a photosensitive or scarring eruption with systemic symptoms (exclude discoid or systemic lupus erythematosus), or a presentation that does not respond as expected to standard rosacea therapy.

• Build the patient's awareness of their individual triggers and how to avoid or minimize them.
• Build the patient's awareness of ocular rosacea signs and symptoms and how to manage them.
• Reduce erythema, flushing, telangiectasia, and inflammatory papules/pustules.
• Improve the visible appearance of the skin, particularly where it is affecting the patient's quality of life.
• Reduce the frequency and severity of cutaneous and ocular flares over time.
• Slow or prevent progression to phymatous change where possible, and refer early when phymatous change is already present.

Trigger identification and avoidance

Ask every patient about their personal triggers and counsel on avoidance — this is one of the highest-yield, lowest-risk interventions in rosacea and should be addressed at every visit, not just at diagnosis.^[5]

Sun protection and general skin care

• Daily broad-spectrum sunscreen, SPF 30 or higher, is one of the most important interventions in rosacea — reinforce this at every visit.
• Use gentle, fragrance-free, non-soap cleansers and moisturizers; avoid astringents and other skincare products that sting or burn on application.
• Avoid topical corticosteroids on the face — they can precipitate or worsen rosacea by adding to the underlying dermal changes, even when used for an unrelated concern.
• Camouflage makeup can help patients whose appearance is affecting their quality of life — green- or yellow-tinted foundation is particularly effective at masking redness in lightly pigmented skin; patients with darkly pigmented skin may benefit from professional cosmetic colour-matching support.

Eyelid hygiene for ocular rosacea

• Gently wash the lids and lashes twice daily with warm water and either a diluted baby shampoo or a commercial lid-care product — apply to a wet washcloth or cotton swab, gently scrub the lid margins and lash base, then rinse with warm water. There is no single consensus technique; some sources recommend a hand-soap-like lather, others undiluted shampoo — either approach is reasonable.
• Use preservative-free artificial tears as needed for dryness.
• Long-chain omega-3 fatty acid supplementation may have a role in dry eye disease including ocular rosacea, though the supporting evidence is inconsistent.
• Evidence for tea tree oil in Demodex-associated blepharitis is limited and uncertain — it is a reasonable adjunct to discuss but should not replace standard lid hygiene.

Laser and light-based procedures

Vascular laser systems and broadband light/intense pulsed light (IPL) devices can significantly improve persistent erythema and telangiectasia after a small number of treatments by selectively targeting the blood vessels causing the redness.^[7] Laser resurfacing and electrosurgery are the definitive options for established, noninflamed phymatous change. All of these are non-pharmacologic, procedure-based options performed by a trained practitioner — pharmacists should know they exist and refer appropriately, but they are not initiated in pharmacy practice. Use caution — and refer to a practitioner experienced with darkly pigmented skin — for any of these procedures in patients with darker skin tones, since hyper- or hypopigmentation, and a higher risk of post-procedure dyschromia and scarring, can occur at higher treatment fluences.

Breastfeeding

Azelaic acid and topical metronidazole are both considered compatible with breastfeeding given limited absorption/low milk transfer — avoid direct infant skin contact with treated areas. Topical brimonidine has no human lactation data but low systemic levels are expected with the cutaneous route; case reports of the related ophthalmic product show no harm to nursing infants. Topical ivermectin has not been studied in breastfeeding but low milk levels are expected given low systemic absorption. Doxycycline, minocycline, and tetracycline transfer into breast milk in low concentrations — short-term use is generally considered compatible with breastfeeding, but prolonged or repeated courses (as often needed in rosacea) should be avoided as a theoretical precaution. Oral isotretinoin is not recommended during breastfeeding — safety has not been documented. Topical cyclosporine ophthalmic emulsion: use with caution — systemic levels after topical ophthalmic use are undetectable, but human lactation data specific to this route are lacking.

Pediatrics

Rosacea is uncommon in children. Azelaic acid, ivermectin, and topical brimonidine have not had safety/effectiveness established under 18, and topical brimonidine is specifically contraindicated under 2 years and not recommended between 2 and 18. Doxycycline, minocycline, and tetracycline are contraindicated up to age 8 because of permanent tooth discolouration and decreased bone growth — pediatric oral therapy is specialist-directed. Oral isotretinoin follows the same age policy detailed in the Acne Vulgaris chapter. Topical cyclosporine ophthalmic emulsion has no authorized pediatric indication.

Renal/hepatic impairment

Doxycycline (either dose) should be used with caution in hepatic impairment or with other hepatotoxic medications; the modified-release product is not recommended after gastrectomy, gastric bypass, or other surgery affecting the duodenum, since its release depends on normal gastric acidity. Isotretinoin needs hepatic and lipid monitoring as detailed in the Acne Vulgaris chapter. Topical agents (azelaic acid, ivermectin, topical metronidazole, topical brimonidine) and topical cyclosporine have minimal systemic absorption and generally need no renal/hepatic dose adjustment.

Older adults

No specific dose adjustment is needed for the topical agents; trials of topical brimonidine, topical metronidazole, and ophthalmic cyclosporine specifically found comparable safety/effectiveness in patients over 65. Watch for drug interactions with oral doxycycline in patients on warfarin (potentiated anticoagulant effect) or a sulfonylurea (potentiated hypoglycemic effect), both more likely to be relevant in an older, more polypharmacy-exposed population.

Reassess topical therapy for papulopustular disease no sooner than 4-8 weeks — topical metronidazole in particular can take up to 3-9 weeks to show its full effect, and judging it a failure earlier risks an unnecessary switch or escalation.^[5] Reassess an oral antibiotic course at about 12 weeks (3 months); many patients can then taper or stop the oral agent while continuing topical maintenance. Because rosacea is a chronic, relapsing disease, relapse after stopping any effective therapy — topical or oral — is expected rather than a sign the wrong drug was chosen; long-term topical maintenance is often needed indefinitely. Specifically monitor for rebound erythema in the first 1-2 weeks of topical brimonidine, and reassess whether to continue, stop, or attempt a cautious retrial with a smaller test area. Ask about ocular symptoms at every follow-up visit for cutaneous rosacea, even when they are not the presenting complaint. For phymatous change, monitor for progression and refer for laser/surgical options before disfigurement or functional (airway) impairment becomes severe. Isotretinoin monitoring (pregnancy testing where applicable, liver enzymes, lipids) follows the schedule detailed in the Acne Vulgaris chapter.

1. Confirm adherence and correct technique/duration before declaring failure — topical metronidazole and azelaic acid both need several weeks of consistent use before their full effect can be judged.
2. Reassess for an unrecognized trigger — a new medication, a new skincare product, or undisclosed topical corticosteroid use — undermining an otherwise appropriate regimen.
3. If one topical agent is inadequate after an adequate trial, switch to a different topical class or combine two topical agents rather than simply extending the same regimen indefinitely.
4. If topical therapy alone remains inadequate for moderate-severe papulopustular disease, add an oral agent — anti-inflammatory-dose doxycycline modified-release first, standard-dose doxycycline/tetracycline as an alternative.
5. For persistent erythema inadequately controlled with brimonidine, or where rebound erythema limits use, refer for vascular laser/IPL rather than escalating the topical dose beyond the labelled maximum.
6. For genuinely treatment-resistant papulopustular disease despite an adequate combined topical-plus-oral trial, move to low-dose oral isotretinoin.
7. For ocular symptoms not responding to lid hygiene plus an oral tetracycline-class antibiotic, refer to ophthalmology for topical cyclosporine and further assessment.
8. At any point where the response pattern does not fit expectations, reconsider the diagnosis — revisit the comparison table in Assessment & Diagnosis, since an apparent treatment failure is sometimes actually a mimic (a steroid-induced rosacea-like eruption in particular can look like "rosacea that isn't responding" when the real issue is ongoing topical corticosteroid exposure).

• Prescribing or continuing a topical corticosteroid on rosacea-affected facial skin — this worsens rosacea and can itself cause a steroid-induced rosacea-like eruption.
• Judging a topical agent a failure before an adequate trial — topical metronidazole and azelaic acid can take several weeks to show their full effect.
• Not asking about ocular symptoms in a patient with cutaneous rosacea — ocular involvement is common and easy to miss unless specifically asked about.
• Starting brimonidine without counselling on rebound erythema — an unwarned patient may believe the medication has made their redness worse when a brief, expected phenomenon is at play, or may fail to recognize a genuine reaction requiring discontinuation.
• Confusing anti-inflammatory (subantimicrobial) dose doxycycline with standard antimicrobial-dose doxycycline — the modified-release, subantimicrobial-dose product must not be used to treat or prevent infections, and only the standard-dose product has supporting evidence for ocular rosacea.
• Combining doxycycline (either dose) with an oral retinoid (isotretinoin) — increased risk of pseudotumor cerebri (benign intracranial hypertension).
• Assuming a papulopustular presentation is acne vulgaris (or vice versa) without checking for comedones — their absence in rosacea and presence in acne is the single most reliable differentiator.
• Missing a rosacea mimic that needs entirely different management — most importantly, a genuine steroid-induced rosacea-like eruption, which needs the corticosteroid stopped, not a stronger rosacea regimen added.
• Assuming oxymetazoline cream is readily available in Canada the way it is in the United States — confirm local product availability before recommending it (see Drug Tables).
• Forgetting sun protection counselling — one of the highest-yield, lowest-risk interventions in rosacea management.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Topical agents for inflammatory papules and pustules

All three are considered comparable 1st-line options; selection is based on tolerability and patient preference.

Topical agents for persistent erythema

Oral antibiotics

Used chiefly for their anti-inflammatory rather than antimicrobial effect in rosacea.

Retinoids

Ocular rosacea